Mechanisms of action of novel agents for prostate cancer chemoprevention

Endocrine-Related Cancer

Volumn 13, Issue 3, 2006, Pages 751-778

  Singh, Rana P ^a   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACACETIN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; APIGENIN; ATM PROTEIN; BETA CATENIN; CURCUMIN; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; HERBACEOUS AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MATRIX METALLOPROTEINASE; PHYTIC ACID; RETINOBLASTOMA PROTEIN; SILIBININ; SOMATOMEDIN RECEPTOR; TELOMERASE; TOLL LIKE RECEPTOR; UROKINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CELL CYCLE; CELL SURVIVAL; CHEMOPROPHYLAXIS; DRUG EFFICACY; GRAPEFRUIT; HUMAN; IN VIVO STUDY; METASTASIS; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR GROWTH; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANTICARCINOGENIC AGENTS; CELL CYCLE; CELL SURVIVAL; CHEMOPREVENTION; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 33751081567     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01126     Document Type: Review

References (267)

1. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Grone HJ, Hallahan DE, Reisfeld RA, Debus J et al. 2005 Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clinical Cancer Research 11 6270-6279.
2. Abdulla M & Gruber P 2000 Role of diet modification in cancer prevention. Biofactors 12 45-51.
3. Adhami VM, Siddiqui IA, Ahmad N, Gupta S & Mukhtar H 2004 Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Research 64 8715-8722.
4. Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G & Sizemore N 2005 The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene 24 1021-1031.
5. Agarwal C, Sharma Y & Agarwal R 2000 Anticarcinogenic effect of a polyphenolic fraction isolated from grape seeds in human prostate carcinoma DU145 cells: modulation of mitogenic signaling and cell-cycle regulators and induction of G1 arrest and apoptosis. Molecular Carcinogenesis 28 129-138.
6. Agarwal C, Singh RP & Agarwal R 2002 Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis 23 1869-1876.
7. Agarwal C, Dhanalakshmi S, Singh RP & Agarwal R 2003 Inositol hexaphosphate inhibits constitutive activation of NF- kappa B in androgen-independent human prostate carcinoma DU145 cells. Anticancer Research 23 3855-3861.
8. Agarwal C, Dhanalakshmi S, Singh RP & Agarwal R 2004a Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neoplasia 6 646-659.
9. Agarwal C, Singh RP, Dhanalakshmi S & Agarwal R 2004b Anti-angiogenic efficacy of grape seed extract in endothelial cells. Oncology Reports 11 681-685.
10. Agarwal R 2000 Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochemical Pharmacology 60 1051-1059.
11. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, Haapakoski J, Rautalahti M, Hartman AM & Palmgren J 1995 Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. American Journal of Clinical Nutrition 62 1427S-1430S.
12. Altieri DC 2003 Validating survivin as a cancer therapeutic target. Nature Reviews Cancer 3 46-54.
13. Angele S, Falconer A, Foster CS, Taniere P, Eeles RA & Hall J 2004 ATM protein overexpression in prostate tumors: possible role in telomere maintenance. American Journal of Clinical Pathology 121 231-236.
14. Baeuerle PA 1998 IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 95 729-731.
15. Bauer AK, Dixon D, DeGraff LM, Cho HY, Walker CR, Malkinson AM & Kleeberger SR 2005 Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. Journal of the National Cancer Institute 97 1778-1781.
16. Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G & Klocker H 2004 Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. European Urology 45 245-251.
17. Bektic J, Guggenberger R, Eder IE, Pelzer AE, Berger AP, Bartsch G & Klocker H 2005 Molecular effects of the isoflavonoid genistein in prostate cancer. Clinical Prostate Cancer 4 124-129.
18. Belvisi L, Riccioni T, Marcellini M, Vesci L, Chiarucci I, Efrati D, Potenza D, Scolastico C, Manzoni L, Lombardo K et al. 2005 Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Molecular Cancer Therapeutics 4 1670-1680.
19. Bemis DL, Capodice JL, Anastasiadis AG, Katz AE & Buttyan R 2005 Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutrition and Cancer 52 202-212.
20. Bergers G & Benjamin LE 2003 Tumorigenesis and the angiogenic switch. Nature Reviews Cancer 3 401-410.
21. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G & Corti A 2006 Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Research 66 1234-1240.
22. Bharti AC, Donato N & Aggarwal BB 2003 Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. Journal of Immunology 171 3863-3871.
23. Bhatia N & Agarwal R 2001 Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate 46 98-107.
24. Biroccio A & Leonetti C 2004 Telomerase as a new target for the treatment of hormone-refractory prostate cancer. Endocrine-Related Cancer 11 407-421.
25. Bloom J & Pagano M 2003 Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Seminars in Cancer Biology 13 41-47.
26. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S & Novario R 2002 Microvessel density in prostate carcinoma. Prostate Cancer and Prostatic Diseases 5 123-127.
27. Bostwick DG & Iczkowski KA 1998 Microvessel density in prostate cancer: prognostic and therapeutic utility. Seminars in Urologic Oncology 16 118-123.
28. Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR et al. 2001 Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Molecular Endocrinology 15 46-56.
29. Catz SD & Johnson J 2003 BCL-2 in prostate cancer: a minireview. Apoptosis 8 29-37.
30. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Henneken CH & Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (Washington DC) 279 563-566.
31. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano M, Pollak M & Giovannucci E 2002 Insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 as predictors of advanced-stage prostate cancer. Journal of the National Cancer Institute 94 1099-1109.
32. Chang KL, Kung ML, Chow NH & Su SJ 2004 Genistein arrests hepatoma cells at G2/M phase: involvement of ATM activation and upregulation of p21waf1/cip1 and Wee1. Biochemical Pharmacology 67 717-726.
33. Chau BN & Wang JY 2003 Coordinated regulation of life and death by RB. Nature Reviews Cancer 3 130-138.
34. Chen T, Wang LH & Farrar WL 2000 Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Research 60 2132-2135.
35. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S & Hunter DJ 2005 Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Research 24 11771-11778.
36. Chendil D, Ranga RS, Meigooni D, Sathishkumar S & Ahmed MM 2004 Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23 1599-1607.
37. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H & Bostwick DG 2000 The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clinical Cancer Research 6 1896-1899.
38. Chesire DR & Isaacs WB 2003 Beta-catenin signaling in prostate cancer: an early perspective. Endocrine-Related Cancer 10 537-560.
39. Chiarugi V, Magnelli L & Gallo O 1998 Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. International Journal of Molecular Medicine 2 715-719.
40. Choan E, Segal R, Jonker D, Malone S, Reaume N, Eapen L & Gallant V 2005 A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urologic Oncology 23 108-113.
41. Choi S & Singh SV 2005 Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Research 65 2035-2043.
42. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP et al. 2001 Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiology Biomarkers and Prevention 10 421-427.
43. Chu SC, Chiou HL, Chen PN, Yang SF & Hsieh YS 2004 Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Molecular Carcinogenesis 40 143-149.
44. Clinton SK & Giovannucci E 1998 Diet, nutrition, and prostate cancer. Annual Review of Nutrition 18 413-440.
45. Cohen P, Peehl DM, Graves HC & Rosenfeld RG 1994 Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. The Journal of Endocrinology 142 407-415.
46. Cox MC, Permenter M & Figg WD 2005 Angiogenesis and prostate cancer: important laboratory and clinical findings. Current Oncology Reports 7 215-219.
47. Dai Y & Grant S 2003 Cyclin-dependent kinase inhibitors. Current Opinion in Pharmacology 3 362-370.
48. Davies G, Jiang WG & Mason MD 2001 The interaction between beta-catenin, GSK3beta and APC after motogen induced cell-cell dissociation, and their involvement in signal transduction pathways in prostate cancer. International Journal of Oncology 18 843-847.
49. Davis JN, Kucuk O & Sarkar FH 1999 Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutrition and Cancer 35 167-174.
50. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA & Gautam SC 2003 Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Molecular Cancer Therapeutics 2 95-103.
51. Deep G, Singh RP, Agarwal C, Kroll DJ & Agarwal R 2006 Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25 1053-1069.
52. Dhanalakshmi S, Singh RP, Agarwal C & Agarwal R 2002 Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 21 1759-1767.
53. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G et al. 2002 Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clinical Cancer Research 8 3438-3444.
54. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, Moats S, Ramirez A, Jorcano J & Conti C 2000 Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. PNAS 97 3455-3460.
55. Edwards J, Krishna NS, Grigor KM & Bartlett JM 2003 Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. British Journal of Cancer 89 552-556.
56. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA & Bristow RG 2004 Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Research 64 8526-8533.
57. Feldman BJ & Feldman D 2001 The development of androgen-independent prostate cancer. Nature Reviews Cancer 1 34-45.
58. Fernandez PL, Hernandez L, Farre X, Campo E & Cardesa A 2002 Alterations of cell cycle-regulatory genes in prostate cancer. Pathobiology 70 1-10.
59. Ferrara N 2002 VEGF and the quest for tumour angiogenesis factors. Nature Reviews Cancer 2 795-803.
60. Fischer OM, Hart S, Gschwind A & Ullrich A 2003 EGFR signal transactivation in cancer cells. Biochemical Society Transactions 31 1203-1208.
61. Flaig T, Agarwal R, Su LJ, Harrison GS, Gustafson D, Glode LMA & phase I 2005 A phase I study of silibinin in hormone refractory prostate cancer. Journal of Clinical Oncology 23 427s.
62. Flynn V, Jr, Ramanitharan A, Moparty K, Davis R, Sikka S, Agrawal KC & Abdel-Mageed AB 2003 Adenovirus-mediated inhibition of NF-kappaB confers chemosensitization and apoptosis in prostate cancer cells. International Journal of Oncology 23 317-323.
63. Ford OH, III, Gregory CW, Kim D, Smitherman AB & Mohler JL 2003 Androgen receptor gene amplification and protein expression in recurrent prostate cancer. The Journal of Urology 170 1817-1821.
64. Fornaro M, Manes T & Languino LR 2001 Integrins and prostate cancer metastases. Cancer and Metastasis Reviews 20 321-331.
65. Fu M, Wang C, Li Z, Sakamaki T & Pestell RG 2004a Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145 5439-5447.
66. Fu XS, Choi E, Bubley GJ & Balk SP 2005 Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 63 215-221.
67. Fu Y, Hsieh TC, Guo J, Kunicki J, Lee MY, Darzynkiewicz Z & Wu JM 2004b Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochemical and Biophysical Research Communications 322 263-270.
68. Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X & Xu DQ 2005 Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clinical Cancer Research 11 6333-6341.
69. Gartel AL & Tyner AL 2002 The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Molecular Cancer Therapeutics 1 639-649.
70. Gasparian AV, Yao YJ, Lu J, Yemelyanov AY, Lyakh LA, Slaga TJ & Budunova S, IV 2002 Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells. Molecular Cancer Therapeutics 1 1079-1087.
71. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih IeM, Buhler K, Pienta K, Rubin MA, Vessella R & Papadopoulos N 2002 APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 34 9-16.
72. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr & Weber MJ 1999 Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Research 59 279-284.
73. Giuliani C, Napolitano G, Bucci I, Montani V & Monaco F 2001 NF-kappaB transcription factor: role in the pathogenesis of inflammatory, autoimmune, and neoplastic diseases and therapy implications. Clinica Terapeutica 152 249-253.
74. Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, Siermann A, Taketo MM, von Boehmer H & Khazaie K 2002 Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21 4099-4107.
75. Grana X & Reddy P 1995 Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKIs). Oncogene 11 211-219.
76. Grimberg A & Cohen P 2000 Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. Journal of Cellular Physiology 183 1-9.
77. Gunawardena K, Campbell LD & Meikle AW 2004 Combination therapy with vitamins C plus E inhibits survivin and human prostate cancer cell growth. Prostate 59 319-327.
78. Guo D, Jia Q, Song HY, Warren RS & Donner DB 1995 Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. Journal of Biological Chemistry 270 6729-6733.
79. Gupta S, Ahmad N, Mohan RR, Husain MM & Mukhtar H 1999 Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Research 59 2115-2120.
80. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM & Mukhtar H 2000 Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Research 60 5125-5133.
81. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P & Mukhtar H 2004a Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Research 64 3334-3343.
82. Gupta S, Hastak K, Afaq F, Ahmad N & Mukhtar H 2004b Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene 23 2507-2522.
83. Hannay JA & Yu D 2003 Silibinin: a thorny therapeutic for EGF-R expressing tumors? Cancer Biology and Therapy 2 532-533.
84. Harman SH, Metter EJ, Blackman MR, Landis PK & Carter HB 2000 Serum levels of insulin-like growth factor 1 (IGF-1), IGF-2, IGF-binding protein-3 and prostate-specific antigen as predictors of clinical prostate cancer. Journal of Clinical Endocrinology and Metabolism 85 4258-4265.
85. Harris AL 2002 Hypoxia - a key regulatory factor in tumour growth. Nature Reviews Cancer 2 38-47.
86. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML & Mukhtar H 2003 Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22 4851-4859.
87. Hastak K, Agarwal MK, Mukhtar H & Agarwal ML 2005 Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB Journal 19 789-791.
88. Hayashi N, Asano K, Suzuki H, Yamamoto T, Tanigawa N, Egawa S & Manome Y 2005 Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 65 10-19.
89. Helenius MA, Saramaki OR, Linja MJ, Tammela TL & Visakorpi T 2001 Amplification of urokinase gene in prostate cancer. Cancer Research 61 5340-5344.
90. Hirai H, Roussel MF, Kato JY, Ashmun RA & Sherr CJ 1995 Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Molecular and Cellular Biology 15 2672-2681.
91. Ho PK & Hawkins CJ 2005 Mammalian initiator apoptotic caspases. The FASEB journal 272 5436-5453.
92. Hong JH, Ahn KS, Bae E, Jeon SS & Choi HY 2006 The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Disease (In Press).
93. Horinaga M, Okita H, Nakashima J, Kanao K, Sakamoto M & Murai M 2005 Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 66 671-675.
94. Hsiung SC, Tamir H, Franke TF & Liu KP 2005 Roles of extracellular signal-regulated kinase and Akt signaling in coordinating nuclear transcription factor-kappaB-dependent cell survival after serotonin IA receptor activation. Journal of Neurochemistry 95 1653-1666.
95. Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC & Bergan RC 2005 Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Research 65 3470-3478.
96. Huang YT, Hwang JJ, Lee PP, Ke FC, Huang JH, Huang CJ, Kandaswami C, Middleton E, Jr & Lee MT 1999 Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. British Journal of Pharmacology 128 999-1010.
97. Husbeck B, Nonn L, Peehl DM & Knox SJ 2006 Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66 218-225.
98. Huynh CK, Brodie AM & Njar VC 2006 Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice. British Journal of Cancer 31.
99. Ishii K, Usui S, Sugimura Y, Yamamoto H, Yoshikawa K & Hiran K 2001 Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biological and Pharmaceutical Bulletin 24 188-190.
100. Jeong S, Itokawa T, Shibuya M, Kuwano M, Ono M, Higuchi R & Miyamoto T 2002 A Sesquiterpene lactone from Saussurea lappa, inhibits the VEGFR KDR/Flk-1 signaling pathway. Cancer Letters 187 129-133.
101. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU & Brady JN 2005 Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 24 6719-6728.
102. Jian L, Xie LP, Lee AH & Binns CW 2004 Protective effect of green tea against prostate cancer: a case-control study in southeast China. International Journal of Cancer 108 130-135.
103. Jiang C, Agarwal R & Lu J 2000 Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochemical and Biophysical Research Communications 276 371-378.
104. Jiang C, Lee HJ, Li GX, Guo J, Malewicz B, Zhao Y, Lee EO, Lee HJ, Lee JH, Kim MS et al. 2006 Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Research 66 453-463.
105. Jones HE, Barrow D, Dutkowski CM, Goddard L, Smith C, Harper ME & Nicholson RI 2001 Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways. Prostate 49 38-47.
106. Karin M, Cao Y, Greten FR & Li ZW 2002 NF-kappaB in cancer: from innocent bystander to major culprit. Nature Reviews Cancer 2 301-310.
107. Kawabe T 2004 G2 checkpoint abrogators as anticancer drugs. Molecular Cancer Therapeutics 3 513-519.
108. Kawai T & Akira S 2006 TLR signaling. Cell Death and Differentiation 20 (In Press).
109. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Malone WA, Hawk ET, Lieberman R, Lawrence JA, Kopelovich L et al. 1999 Progress in cancer chemoprevention. Annals of the New York Academy of Sciences 889 1-13.
110. Kerbel RS 2000 Tumor angiogenesis: past, present and the near future. Carcinogenesis 21 505-515.
111. Khor TO, Keum YS, Lin W, Kim JH, Hu R, Shen G, Xu C, Gopalakrishnan A, Reddy B, Zheng X et al. 2006 Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Research 66 613-621.
112. Kim HY, Park EJ, Joe EH & Jou I 2003 Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. Journal of Immunology 171 6072-6079.
113. Kim MS, Lee YM, Moon EJ, Kim SE, Lee JJ & Kim KW 2000 Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica. International Journal of Cancer 87 269-275.
114. Kim NW & Hruszkewycz AM 2001 Telomerase activity modulation in the prevention of prostate cancer. Urology 57 148-153.
115. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL & Shay JW 1994 Specific association of human telomerase activity with immortal cells and cancer. Science 266 2011-2015.
116. Kim WY & Kaelin WG 2004 Role of VHL gene mutation in human cancer. Journal of Clinical Oncology 22 4991-5004.
117. Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, Gho YS & Kwon YG 2002 Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. The Journal of Biological Chemistry 277 27872-27879.
118. Kirsch M, Schackert G & Black PM 2004 Metastasis and angiogenesis. Cancer Treatment and Research 117 285-304.
119. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S & Shiina H 2004 Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. The Journal of Urology 171 1855-1860.
120. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR & Coltman C 2000 SELECT: the Selenium and Vitamin E cancer prevention trial: rationale and design. Prostate Cancer Prostatic Disease 3 145-151.
121. Konig JE, Senge T, Allhoff EP & Konig W 2004 Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 58 121-129.
122. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D et al. 2003 Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clinical Cancer Research 9 4914-4925.
123. Kumar S, Suresh PK, Vijayababu MR, Arunkumar A & Arunakaran J 2005 Anticancer effects of ethanolic neem leaf extract on prostate cancer cell line (PC-3). Journal of Ethnopharmacology 22 (In Press).
124. LaCasse EC, Baird S, Korneluk RG & MacKenzie AE 1998 The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 3247-3259.
125. Lage A, Crombet T & Gonzalez G 2003 Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Annals of Medicine 35 327-336.
126. Lamy S, Gingras D & Beliveau R 2002 Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylations. Cancer Research 62 381-385.
127. Lara PN, Jr, Twardowski P & Quinn DI 2004 Angiogenesis-targeted therapies in prostate cancer. Clinical Prostate Cancer 3 165-173.
128. Lee HH, Ho CT & Lin JK 2004a Theaflavin-3,3′-digallate and penta-O-galloyl-beta-D-glucose inhibit rat liver microsomal 5alpha-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 25 1109-1118.
129. Lee JH, Cheong J, Park YM & Choi YH 2005 Down-regulation of cyclooxygenase-2 and telomerase activity by beta-lapachone in human prostate carcinoma cells. Pharmacological Research 51 553-560.
130. Lee KM, Yeo M, Choue JS, Jin JH, Park SJ, Cheong JY, Lee KJ, Kim JH & Hahm KB 2004b Protective mechanism of epigallocatechin-3-gallate against Helicobacter pylori-induced gastric epithelial cytotoxicity via the blockage of TLR-4 signaling. Helicobacter 9 632-642.
131. Li Y, Che M, Bhagat S, Ellis KL, Kucuk O, Doerge DR, Abrams J, Cher ML & Sarkar FH 2004 Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 6 354-363.
132. Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, Angel P & Mayer D 2005 Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Human Pathology 36 1186-1196.
133. Lin PH, Pan Z, Zheng L, Li N, Danielpour D & Ma JJ 2005 Overexpression of Bax sensitizes prostate cancer cells to TGF-beta induced apoptosis. Cell Research 15 160-166.
134. Lin Y, Uemura H, Fujinami K, Hosaka M, Harada M & Kubota Y 1997 Telomerase activity in primary prostate cancer. The Journal of Urology 157 1161-1165.
135. Lindholm PF, Bub J, Kaul S, Shidham VB & Kajdacsy-Balla A 2000 The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior. Clinical and Experimental Metastasis 18 471-479.
136. Liu Y, Martindale JL, Gorospe M & Holbrook NJ 1996 Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Research 56 31-35.
137. Lloyd FP, Jr, Slivova V, Valachovicova T & Sliva D 2003 Aspirin inhibits highly invasive prostate cancer cells. International Journal of Oncology 23 1277-1283.
138. Lorenzo GD, Bianco R, Tortora G & Ciardiello F 2003 Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clinical Prostate Cancer 2 50-57.
139. Lu X, Hsieh TC & Wu JM 2004 Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c. International Journal of Oncology 25 1801-1807.
140. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H & Simons JW 2003 Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clinical Cancer Research 9 2416-2425.
141. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN & Mukhtar H 2005 Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. PNAS 102 14813-14818.
142. Mallikarjuna G, Dhanalakshmi S, Singh RP, Agarwal C & Agarwal R 2004 Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Research 64 6349-6356.
143. Mathon NF & Lloyd AC 2001 Cell senescence and cancer. Nature Reviews Cancer 1 203-213.
144. Matsuda T, Junicho A, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H & Muraguchi A 2001 A cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochemical and Biophysical Research Communications 283 179-187.
145. McCarty MF 2004 Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integrative Cancer Therapies 3 349-380.
146. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE & Leung HY 2003 MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 22 1381-1389.
147. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L & Senderowicz AM 1999 Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Research 59 5433-5437.
148. Mendelsohn J & Baselga J 2000 The EGF receptor family as targets for cancer therapy. Oncogene 19 6550-6565.
149. Mittal A, Pate MS, Wylie RC, Tollefsbol TO & Katiyar SK 2004 EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. International Journal of Oncology 24 703-710.
150. Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, Agarwal R, Marengo SR, Amini SB, Paras F, MacLennan GT et al. 1999 Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clinical Cancer Research 5 143-147.
151. Mohler JL, Gregory CW, Ford OH, III, Kim D, Weaver CM, Petrusz P, Wilson EM & French FS 2004 The androgen axis in recurrent prostate cancer. Clinical Cancer Research 10 440-448.
152. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A et al. 2002 Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Research 62 6659-6666.
153. Morris JD, Pramanik R, Zhang X, Carey AM, Ragavan N, Martin FL & Muir GH 2005 Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity. Cancer Letters 17 (In Press).
154. Moul JW 1999 Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. European Urology 35 399-407.
155. Mukhopadhyay UK, Senderowicz AM & Ferbeyre G 2005 RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Research 65 2872-2881.
156. Myers RB, Srivastava S, Oelschlager DK & Grizzle WE 1994 Expression of p160erbB3 and p185erbB2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Journal of the National Cancer Institute 86 1140-1145.
157. Narayanan NK, Narayanan BA & Reddy BS 2005 A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. International Journal of Oncology 26 785-792.
158. Nelson WG, De Marzo AM & Isaacs WB 2003 Prostate cancer. New England Journal of Medicine 349 366-381.
159. Neumann AA & Reddel RR 2002 Telomere maintenance and cancer - look, no telomerase. Nature Reviews Cancer 2 879-884.
160. Ni Z, Lou W, Leman ES & Gao AC 2000 Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Research 60 1225-1228.
161. Nickerson T & Huynh H 1999 Vitamin D analogue EB 1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. The Journal of Endocrinology 160 223-229.
162. Nilsson I & Hoffmann I 2000 Cell cycle regulation by the Cdc25 phosphatase family. Progress in Cell Cycle Research 4 107-114.
163. O'Prey J, Brown J, Fleming J & Harrison PR 2003 Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells. Biochemical Pharmacology 66 2075-2088.
164. Orlando C, Gelmini S, Selli C & Pazzagli M 2001 Telomerase in urological malignancy. The Journal of Urology 166 666-673.
165. Ortega S, Malumbres M & Barbacid M 2002 Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochimica et Biophysica Acta 1602 73-87.
166. Overall CM & Lopez-Otin C 2002 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Reviews Cancer 2 657-672.
167. Paggi MG, Baldi A, Bonetto F & Giordano A 1996 Retinoblastoma protein family in cell cycle and cancer: a review. Journal of Cellular Biochemistry 62 418-430.
168. Park OJ & Surh YJ 2004 Chemopreventive potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicology Letters 150 43-56.
169. Pezzato E, Sartor L, Dell'Aica I, Dittadi R, Gion M, Belluco C, Lise M & Garbisa S 2004 Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin- 3-gallate. International Journal of Cancer 112 787-792.
170. Pienta KJ & Loberg R 2005 The "emigration, migration, and immigration" of prostate cancer. Clinical Prostate Cancer 4 24-30.
171. Potter JD & Steinmetz K 1996 Vegetables, fruit and phytoestrogens as preventive agents. IARC Scientific Publications 139 61-90.
172. Pugh CW & Ratcliffe PJ 2003 The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Seminars in Cancer Biology 13 83-89.
173. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M & Rao JS 2005 RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. Journal of Biological Chemistry 280 36529-36540.
174. Qi L, Singh RP, Lu Y, Agarwal R, Harrison GS, Franzusoff A & Glode LM 2003 Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biology and Therapy 2 526-531.
175. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS & Buttyan R 1995 Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Research 55 4438-4445.
176. Rajasingh J, Raikwar HP, Muthian G, Johnson C & Bright JJ 2006 Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. Biochemical and Biophysical Research Communications 340 359-368.
177. Rapella A, Negrioli A, Melillo G, Pastorino S, Varesio L & Bosco MC 2002 Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. International Journal of Cancer 99 658-664.
178. Ravindranath N, Ioffe SL, Marshall GR, Ramaswamy S, Plant TM & Dym M 2001 Androgen depletion activates telomerase in the prostate of the nonhuman primate, Macaca mulatta. Prostate 49 79-89.
179. Reed JC 2002 Apoptosis-based therapies. Nature Reviews. Drug Discovery 1 111S-121S.
180. Rodriguez SK, Guo W, Liu L, Band MA, Paulson EK & Meydani M 2006 Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. International Journal of Cancer 118 1635-1644.
181. Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B, Theodorou E & Jacks T 2000 Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes and Development 14 3037-3050.
182. Sarkar FH & Li Y 2004 Indole-3-carbinol and prostate cancer. The Journal of Nutrition 134 3493S-3498S.
183. Sartippour MR, Heber D, Zhang L, Beatty P, Elashoff D, Elashoff R, Go VL & Brooks MN 2002 Inhibition of fibroblast growth factors by green tea. International Journal of Oncology 21 487-491.
184. Sartor L, Pezzato E, Dona M, Dell'Aica I, Calabrese F, Morini M, Albini A & Garbisa S 2004 Prostate carcinoma and green tea: (-)epigallocatechin-3- gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. International Journal of Cancer 112 823-829.
185. Scher HI & Sawyers CL 2005 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology 23 8253-8261.
186. Schmitz ML & Baeuerle PA 1995 Multi-step activation of NF-kappa B/Rel transcription factors. Immunobiology 193 116-127.
187. Senderwicz AM & Sausville EA 2000 Preclinical and clinical development of cyclin-dependent kinase modulators. Journal of the National Cancer Institute 92 376-387.
188. Seville LL, Shah N, Westwell AD & Chan WC 2005 Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Current Cancer Drug Targets 5 159-170.
189. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM & Ashfaq R 2004 Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100 751-757.
190. Sharma G, Singh RP & Agarwal R 2003 Growth inhibitory and apoptotic effects of inositol hexaphosphate in transgenic adenocarcinoma of mouse prostate (TRAMP-C1) cells. International Journal of Oncology 23 1413-1418.
191. Sharma Y, Agarwal C, Singh AK & Agarwal R 2001 Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Molecular Carcinogenesis 30 224-236.
192. Sheng S 2001 The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer and Metastasis Reviews 20 287-296.
193. Sherr CJ 2000 The pezcoller lecture: Cancer cell cycle revisited. Cancer Research 60 3689-3695.
194. Sherr CJ & Roberts JM 1999 CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & Development 13 1501-1512.
195. Shukla S & Gupta S 2004a Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Molecular Carcinogenesis 39 114-126.
196. Shukla S & Gupta S 2004b Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clinical Cancer Research 10 3169-3178.
197. Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI & Gupta S 2005 Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB Journal 19 2042-2044.
198. Singh AS & Figg WD 2005 In vivo models of prostate cancer metastasis to bone. Journal of Urology 174 820-826.
199. Singh RP & Agarwal R 2003 Tumor angiogenesis: a potential target in cancer control by phytochemicals. Current Cancer Drug Targets 3 205-217.
200. Singh RP & Agarwal R 2004 Prostate cancer prevention by silibinin. Current Cancer Drug Targets 4 1-11.
201. Singh RP & Agarwal R 2005 Prostate cancer and inositol hexaphosphate: efficacy and mechanisms. Anticancer Research 25 2891-2903.
202. Singh RP, Dhanalakshmi S & Agarwal R 2002c Phytochemicals as cell cycle modulators - a less toxic approach in halting human cancers. Cell Cycle 1 156-161.
203. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C & Agarwal R 2002b Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Research 62 3063-3069.
204. Singh RP, Agarwal C & Agarwal R 2003a Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 24 555-563.
205. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C & Agarwal R 2003b Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiology, Biomarkers and Prevention 12 933-939.
206. Singh RP, Sharma G, Mallikarjuna GU, Dhanalakshmi S, Agarwal C & Agarwal R 2004a In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clinical Cancer Research 10 244-250.
207. Singh RP, Tyagi AK, Dhanalakshmi S, Agarwal R & Agarwal C 2004b Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. International Journal of Cancer 108 733-740.
208. Singh RP, Agrawal P, Yim D, Agarwal C & Agarwal R 2005a Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: structure-activity relationship with linarin and linarin acetate. Carcinogenesis 26 845-854.
209. Singh RP, Dhanalakshmi S, Agarwal C & Agarwal R 2005b Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and down-regulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24 1188-1202.
210. Singh SV, Zeng Y, Xiao D, Vogel VG, Nelson JB, Dhir R & Tripathi YB 2005c Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak. Molecular Cancer Therapeutics 4 1747-1754.
211. Skogseth H, Larsson E & Halgunset J 2005 Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells. Acta Pathologica, Microbiologica et Immunologica Scandinavica 113 332-339.
212. Slack-Davis JK & Parsons JT 2004 Emerging views of integrin signaling: implications for prostate cancer. Journal of Cellular Biochemistry 91 41-46.
213. Slansky JE & Farnham PJ 1996 Introduction to the E2F family: protein structure and gene regulation. Current Topics in Microbiology and Immunology 208 1-30.
214. Sommer A & Haendler B 2003 Androgen receptor and prostate cancer: molecular aspects and gene expression profiling. Current Opinion in Drug Discovery and Development 6 702-711.
215. Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M & Barbacid M 2001 Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO Journal 20 6637-6647.
216. Stewart JR, Artime MC & O'Brian CA 2003 Resveratrol: a candidate nutritional substance for prostate cancer prevention. Journal of Nutrition 133 2440S-2443S.
217. Suh J & Rabson AB 2004 NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? Journal of Cellular Biochemistry 91 100-117.
218. Sumitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F, Hayakawa M & Nakamura H 1999 An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. Journal of Urology 161 674-679.
219. Sun J, Wiklund F, Zheng SL, Chang B, Balter K, Li L, Johansson JE, Li G, Adami HO, Liu W et al. 2005 Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. Journal of the National Cancer Institute 97 525-532.
220. Suzuki K, Koike H, Matsui H, Ono Y, Hasumi M, Nakazato H, Okugi H, Sekine Y, Oki K, Ito K et al. 2002 Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. International Journal of Cancer 99 846-852.
221. Takaha N, Resar LM, Vindivich D & Coffey DS 2004 High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 60 160-167.
222. Tenzer A & Pruschy M 2003 Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators. Current Medicinal Chemistry. Anti-Cancer Agents 3 35-46.
223. Thelen P, Wuttke W, Jarry H, Grzmil M & Ringert RH 2004 Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. Journal of Urology 171 1934-1938.
224. Titus MA, Schell MJ, Lih FB, Tomer KB & Mohler JL 2005 Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 11 4653-4657.
225. Toyoshima H & Hunter T 1994 P27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78 67-74.
226. Truman JP, Gueven N, Lavin M, Leibel S, Kolesnick R, Fuks Z & Haimovitz-Friedman A 2005 Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. Journal of Biological Chemistry 280 23262-23272.
227. Tsihlias J, Kapusta L & Slingerland J 1999 The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annual Review of Medicine 50 401-423.
228. Tsuda H, Ohshima Y, Nomoto H, Fujita K, Matsuda E, Iigo M, Takasuka N & Moore MA 2004 Cancer prevention by natural compounds. Drug Metabolism and Pharmacokinetics 19 245-263.
229. Turner HE, Harris AL, Melmed S & Wass JA 2003 Angiogenesis in endocrine tumors. Endocrine Reviews 24 600-632.
230. Tyagi A, Agarwal C & Agarwal R 2002a Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Molecular Cancer Therapeutics 1 525-532.
231. Tyagi A, Agarwal C & Agarwal R 2002b The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells. Cell Cycle 1 137-142.
232. Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C & Agarwal R 2002c Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate 53 211-217.
233. Tyagi AK, Singh RP, Agarwal C, Chan DC & Agarwal R 2002d Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clinical Cancer Research 8 3512-3519.
234. Tyagi A, Agarwal R & Agarwal C 2003a Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene 22 1302-1316.
235. Tyagi AK, Agarwal C, Singh RP, Shroyer KR, Glode LM & Agarwal R 2003b Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochemical and Biophysical Research Communications 312 1178-1184.
236. Venkateswaran V, Fleshner NE & Klotz LH 2004 Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. Prostate Cancer and Prostatic Diseases 7 54-56.
237. Vermeulen K, Van Bockstaele DR & Berneman ZN 2003 The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferation 36 131-149.
238. Vijayababu MR, Kanagaraj P, Arunkumar A, Ilangovan R, Aruldhas MM & Arunakaran J 2005 Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. Journal of Cancer Research and Clinical Oncology 131 765-771.
239. Vucenik I, Passaniti A, Vitolo MI, Tantivejkul K, Eggleton P & Shamsuddin AM 2004 Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis 25 2115-2123.
240. Wang J, Eltoum IE & Lamartiniere CA 2004 Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Molecular and Cellular Endocrinology 219 171-180.
241. Wasylyk B, Hahn SJ & Giovane A 1993 The Ets family of transcription factors. European Journal of Biochemistry 211 7-18.
242. Watson JL, Ansari S, Cameron H, Wang A, Akhtar M & McKay DM 2004 Green tea polyphenol (-) -epigallocatechin gallate blocks epithelial barrier dysfunction provoked by IFN-gamma but not by IL-4. American Journal of Physiology. Gastrointestinal and Liver Physiology 287 G954-G961.
243. Watson RW & Fitzpatrick JM 2005 Targeting apoptosis in prostate cancer: focus on caspases and inhibitors of apoptosis proteins. BJU International 96 (S2)30-(S2)34.
244. Webber MM & Waghray A 1995 Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clinical Cancer Research 1 755-761.
245. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J & Davis RJ 1998 A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281 1671-1674.
246. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM & West DW 1995 Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. Journal of the National Cancer Institute 87 652-661.
247. Xiao D & Singh SV 2006 Diallyl trisulfide, a constituent of processed garlic, inactivates Akt to trigger mitochondrial translocation of BAD and caspase-mediated apoptosis in human prostate cancer cells. Carcinogenesis 27 533-540.
248. Xiao D, Zeng Y, Choi S, Lew KL, Nelson JB & Singh SV 2005 Caspase-dependent apoptosis induction by phenethyl isothiocyanate, a cruciferous vegetable-derived cancer chemopreventive agent, is mediated by Bak and Bax. Clinical Cancer Research 11 2670-2679.
249. Xing N, Chen Y, Mitchell SH & Young CY 2001 Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22 409-414.
250. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi XX & Beach D 1993 P21 is a universal inhibitor of cyclin kinases. Nature 366 701-704.
251. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U & Gleave ME 2005 A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Molecular Cancer Therapeutics 4 1689-1698.
252. Yang J, Yu Y, Hamrick HE & Duerksen-Hughes PJ 2003 ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis 24 1571-1580.
253. Yardy GW & Brewster SF 2005 Wnt signalling and prostate cancer. Prostate Cancer and Prostatic Diseases 8 119-126.
254. Yim D, Singh RP, Agarwal C, Lee S, Chi H & Agarwal R 2005 A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Research 65 1035-1044.
255. Yu H & Rohan T 2000 Role of insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 92 1472-1489.
256. Yu H & Jove R 2004 The STATs of cancer - new molecular targets come of age. Nature Reviews. Cancer 4 97-105.
257. Zhang M, Altuwaijri S & Yeh S 2004 RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene 23 3080-3088.
258. Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR et al. 2004 Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Research 64 2918-2922.
259. Zhong H, Demarzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL & Simons JW 1999 Overexpression of hypoxia-inducible factor-1α in common human cancers and their metastases. Cancer Research 59 5830-5835.
260. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons J & Semenza GL 2000 Modulatipn of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Research 60 1541-1545.
261. Zhou BB, Anderson HJ & Roberge M 2003 Targeting DNA checkpoint kinases in cancer therapy. Cancer Biology and Therapy 2 16S-22S.
262. Zhu W, Smith A & Young CY 1999 A nonsteroidal antiinflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology 140 5451-5454.
263. Zhu W, Zhang JS & Young CY 2001 Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22 1399-1403.
264. Zi X & Agarwal R 1999 Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. PNAS 96 7490-7495.
265. Zi X, Grasso AW, Kung H & Agarwal R 1998 A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Research 58 1920-1929.
266. Zi X, Singh RP & Agarwal R 2000a Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 21 2225-2235.
267. Zi X, Zhang J, Agarwal R & Pollak M 2000b Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Research 60 5617-5620.